For research use only. Not for therapeutic Use.
Piperacillin(Cat No.:R011373)is a broad-spectrum beta-lactam antibiotic belonging to the penicillin class, widely used in bacterial infection research. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Effective against Gram-negative and some Gram-positive bacteria, Piperacillin is often combined with beta-lactamase inhibitors, such as tazobactam, to combat resistance. Its applications include studying bacterial resistance mechanisms, pharmacokinetics, and optimizing antibiotic therapies. Piperacillin is essential in developing advanced treatments for respiratory, urinary, and intra-abdominal infections.
Catalog Number | R011373 |
CAS Number | 61477-96-1 |
Synonyms | (2S,5R,6R)-6-[[(2R)-2-[[(4-Ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid; CL 227193; Isipen; Pentcillin; Pipracil; T 1220; ? |
Molecular Formula | C23H27N5O7S |
Purity | ≥95% |
Target | Bacterial |
Storage | -20°C |
IUPAC Name | (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
InChI | InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1 |
InChIKey | IVBHGBMCVLDMKU-GXNBUGAJSA-N |
SMILES | CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O |
Reference | <p>Guzmán, Flavio, MD. /Beta Lactams Antibiotics (penicillins and Cephalosporins) Mechanism of Action.” <em>Medical Pharmacology</em>. Pharmacology Corner, 29 Nov. 2008. Web. 21 Aug. 2012.</p><p>Ogawa Y. and Mii M., Screening for highly active Ë-lactam antibiotics against Agrobacterium tumefaciens. Arch Microbiol, Vol. 181, pp. 331-336, 2004.</p><p>Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med 1997; 103:51.</p></span></p> |